Search research articles
Contact Us
Filters
Showing results (61-70 of 127) with videos related to
Page
of 13
Sort By:
Annals of Neurology
|
May 5, 2017
Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α-synuclein Parkinson's disease rat model
Thomas Musacchio, Maike Rebenstorff, Felix Fluri, et al.
Archives of Neurology
|
September 13, 2006
Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease
Susan H Fox, Naomi P Visanji, Tom H Johnston, et al.
Clinical Neuropharmacology
|
August 21, 2004
Levetiracetam Interferes With the L-dopa priming process in MPTP-lesioned drug-naive marmosets
Michael P Hill, Jonathan M Brotchie, Alan R Crossman, et al.
European Journal of Pharmacology
|
February 6, 2004
Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque
Erwan Bezard, Michael P Hill, Alan R Crossman, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
|
February 23, 2010
Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease
Susan H Fox, Naomi Visanji, Gaby Reyes, et al.
Behavioural Brain Research
|
June 23, 2022
Temporal, spatial and molecular pattern of dopaminergic neurodegeneration in the AAV-A53T α-synuclein rat model of Parkinson's disease
Thomas Musacchio, Jing Yin, Fabian Kremer, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|
January 12, 2013
The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques
James B Koprich, Philippe Huot, Susan H Fox, et al.
Molecular Neurobiology
|
May 15, 2015
Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease
Qing He, James B Koprich, Ying Wang, et al.
Journal of Neuroinflammation
|
March 22, 2023
Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson's disease
Alexander Grotemeyer, Judith F Fischer, James B Koprich, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 9, 2004
Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease
Michael P Hill, Paula Ravenscroft, Erwan Bezard, et al.
Page
of 13
Search research articles
Search
Showing results (61-70 of 127) with videos related to
Sort By:
Page
of 13
Annals of Neurology
|
May 5, 2017
Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α-synuclein Parkinson's disease rat model
Thomas Musacchio, Maike Rebenstorff, Felix Fluri, et al.
Archives of Neurology
|
September 13, 2006
Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease
Susan H Fox, Naomi P Visanji, Tom H Johnston, et al.
Clinical Neuropharmacology
|
August 21, 2004
Levetiracetam Interferes With the L-dopa priming process in MPTP-lesioned drug-naive marmosets
Michael P Hill, Jonathan M Brotchie, Alan R Crossman, et al.
European Journal of Pharmacology
|
February 6, 2004
Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque
Erwan Bezard, Michael P Hill, Alan R Crossman, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
|
February 23, 2010
Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease
Susan H Fox, Naomi Visanji, Gaby Reyes, et al.
Behavioural Brain Research
|
June 23, 2022
Temporal, spatial and molecular pattern of dopaminergic neurodegeneration in the AAV-A53T α-synuclein rat model of Parkinson's disease
Thomas Musacchio, Jing Yin, Fabian Kremer, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|
January 12, 2013
The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques
James B Koprich, Philippe Huot, Susan H Fox, et al.
Molecular Neurobiology
|
May 15, 2015
Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease
Qing He, James B Koprich, Ying Wang, et al.
Journal of Neuroinflammation
|
March 22, 2023
Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson's disease
Alexander Grotemeyer, Judith F Fischer, James B Koprich, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 9, 2004
Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease
Michael P Hill, Paula Ravenscroft, Erwan Bezard, et al.
Page
of 13